Aclaris Therapts (ACRS) Stock Price, Quote & News

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JA...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 324 7933

Website: www.aclaristx.com

Address:

701 Lee Road, Suite 103, Wayne, United States

AtomicAIerts Dec. 5 at 11:55 AM

$ACRS AtomicAlerts Scalp Alert Direction: LONG Entry: $3.02 TP1: $3.72 | TP2: $4.42 | TP3: $5.12 Stop Loss: $2.42 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 6:31 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACRS Contract: Dec 19 $3C Entry: 0.30 Exit: 0.41 Return: +35.99% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Doozio Dec. 5 at 1:09 AM

Still got $ACRS to run because it was always 🐒🍌🧠⏰♾️. Let’s bang bro.

0 · Reply

Iightning Dec. 5 at 12:20 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACRS Contract: Dec 19 $3C Entry: 0.30 Exit: 0.41 Return: +35.99% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

OriginalTradeonrumor Dec. 4 at 8:24 PM

$ACRS 3’s!!! Need a close over $3.20 now and then things get much more interesting regarding ability to go to 3.50-3.75 pretty quickly ….but close above $3.20 is needed first. Until then congrats to all who have bought under $3!

0 · Reply

Puffyk Dec. 4 at 7:05 PM

$ACRS 2026 looking like the set-up to $15

0 · Reply

edvquye Dec. 4 at 5:28 PM

$ACRS taking some out here gf wants more lulu congrats longs

0 · Reply

Acan1219 Dec. 4 at 4:38 PM

$ACRS Boom! $3’s

0 · Reply

Btolz Dec. 4 at 4:15 PM

$ACRS Lets break into 3's

0 · Reply

Acan1219 Dec. 4 at 3:42 PM

$ACRS Let’s Gooooo My Bull’s!!

0 · Reply

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 6:59 AM EST - 4 weeks ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 7:30 AM EDT - 5 weeks ago

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct 14, 2025, 5:46 PM EDT - 7 weeks ago

Aclaris Therapeutics, Inc. - Special Call

Sep 30, 2025, 7:00 AM EDT - 2 months ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 9, 2025, 7:00 AM EDT - 3 months ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aug 27, 2025, 8:00 AM EDT - 3 months ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 7, 2025, 6:59 AM EDT - 4 months ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 29, 2025, 4:01 PM EDT - 4 months ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 28, 2025, 8:45 AM EDT - 4 months ago

Aclaris Therapeutics Announces Leadership Transition

Jun 30, 2025, 9:31 AM EDT - 5 months ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 4:01 PM EDT - 5 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 23, 2025, 6:59 AM EDT - 5 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

May 28, 2025, 9:20 AM EDT - 6 months ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 9, 2025, 7:00 AM EDT - 7 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 8, 2025, 6:50 AM EDT - 7 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 7:00 AM EDT - 7 months ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Mar 4, 2025, 7:00 AM EST - 9 months ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Feb 12, 2025, 6:50 AM EST - 10 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Jan 30, 2025, 4:01 PM EST - 11 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 6, 2025, 4:30 PM EST - 11 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 23, 2024, 1:41 PM EST - 1 year ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Nov 26, 2024, 4:30 PM EST - 1 year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 3:27 PM EST - 1 year ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 1 year ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 7, 2024, 9:44 PM EDT - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Feb 27, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Jan 10, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Dec 19, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Provides Corporate Update

Dec 5, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Nov 13, 2023, 7:19 AM EST - 2 years ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Oct 3, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Sep 28, 2023, 7:18 AM EDT - 2 years ago

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Sep 20, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Sep 14, 2023, 7:03 PM EDT - 2 years ago

Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Jul 11, 2023, 7:31 PM EDT - 2 years ago

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

AtomicAIerts Dec. 5 at 11:55 AM

$ACRS AtomicAlerts Scalp Alert Direction: LONG Entry: $3.02 TP1: $3.72 | TP2: $4.42 | TP3: $5.12 Stop Loss: $2.42 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 6:31 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACRS Contract: Dec 19 $3C Entry: 0.30 Exit: 0.41 Return: +35.99% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Doozio Dec. 5 at 1:09 AM

Still got $ACRS to run because it was always 🐒🍌🧠⏰♾️. Let’s bang bro.

0 · Reply

Iightning Dec. 5 at 12:20 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACRS Contract: Dec 19 $3C Entry: 0.30 Exit: 0.41 Return: +35.99% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

OriginalTradeonrumor Dec. 4 at 8:24 PM

0 · Reply

Puffyk Dec. 4 at 7:05 PM

$ACRS 2026 looking like the set-up to $15

0 · Reply

edvquye Dec. 4 at 5:28 PM

$ACRS taking some out here gf wants more lulu congrats longs

0 · Reply

Acan1219 Dec. 4 at 4:38 PM

$ACRS Boom! $3’s

0 · Reply

Btolz Dec. 4 at 4:15 PM

$ACRS Lets break into 3's

0 · Reply

Acan1219 Dec. 4 at 3:42 PM

$ACRS Let’s Gooooo My Bull’s!!

0 · Reply

Bionco Dec. 4 at 3:29 PM

$ACRS we are going to cross $3.X soon

0 · Reply

Iightning Dec. 4 at 7:58 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACRS Contract: Dec 19 $2C Entry: 0.90 Exit: 1.67 Return: +86.05% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

buymoremakemore Dec. 3 at 8:14 PM

$ACRS youre damn right, Thomas

0 · Reply

buymoremakemore Dec. 3 at 2:15 PM

$ACRS FINALLY this CRVS mouthpiece on X talks about ACRS. https://x.com/hothomaswphelps/status/1996216150066160121?s=46

0 · Reply

Acan1219 Dec. 2 at 5:24 PM

$ACRS In @2.61 Let’s Goooo My Bull’s!!

0 · Reply

Iightning Dec. 2 at 2:28 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ACRS **Contract:** Dec 19 $5C **Entry:** 0.26 **Exit:** 0.39 **Return:** **+48.04% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

vu_jade Dec. 1 at 7:16 PM

$ACRS buy the dip

0 · Reply

merlin8121 Nov. 28 at 10:16 AM

$ACRS https://www.merlintrader.com/acrs-aclaris-therapeutics-inc/

0 · Reply

Bionco Nov. 26 at 9:05 PM

$ACRS we got closer to $3.0

0 · Reply

buymoremakemore Nov. 26 at 3:46 PM

$ACRS 1 year ago this was at $4 and $3. The rich catalysts in 2026 we should have at least $5 in runup alone

0 · Reply

OriginalTradeonrumor Nov. 26 at 3:10 PM

$CRDF hmmm…both my largest bio holdings this $ACRS shooting up at same time…must be some tute balancing happening …I’ll take it!!

0 · Reply

Bionco Nov. 26 at 2:54 PM

$ACRS holding strong!

0 · Reply

Market Cap	292.53M
Revenue (ttm)	18.72M
Net Income (ttm)	-132.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-705.50%
Debt to Equity Ratio	0.00

Volume	1,616,600
Avg Vol	1,270,706
Day's Range	N/A - N/A
Shares Out	108.35M
Stochastic %K	76%
Beta	0.62
Analysts	Strong Sell
Price Target	$7.67